scispace - formally typeset
X

Xiaoyan Jiang

Researcher at Tongji University

Publications -  209
Citations -  11393

Xiaoyan Jiang is an academic researcher from Tongji University. The author has contributed to research in topics: Myeloid leukemia & Stem cell. The author has an hindex of 40, co-authored 186 publications receiving 10162 citations. Previous affiliations of Xiaoyan Jiang include BC Cancer Agency & Harbin Medical University.

Papers
More filters
Journal ArticleDOI

Association Study of Mitochondrial DNA Haplogroup D and C5178A Polymorphisms with Chronic Kidney Disease.

TL;DR: The D and D5 haplogroups, as well as the 5178A allele, are associated with decreased eGFR levels and an increased risk of CKD in a longevous population.
Journal ArticleDOI

The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events

TL;DR: Peripheral blood NLR levels at the time of initial diagnosis and treatment had better diagnostic and predictive value for the progression of future thrombotic events in patients with PV than age ≥ 60 years, history of previousThrombosis, and fibrinogen.
Journal ArticleDOI

Puncta intended: connecting the dots between autophagy and cell stress networks

TL;DR: The fourth Vancouver Autophagy Symposium showcased research that expands the understanding of the protein interaction networks and molecular mechanisms underlying autophagy and other cellular stress responses in the context of distinct stressors.
Journal ArticleDOI

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

TL;DR: It is demonstrated that a combination ofmiR-145 and miR-708 are effective predictors of NL response in treatment-naïve patients whereas miCFC output in these panels enhanced predictive performance, and this novel predictive model may be developed into a prognostic tool for use in the clinic.
Journal ArticleDOI

Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34+ Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.

TL;DR: The CML clone in chronic phase patients contains a similar hierarchy of short and longterm repopulating cells as is found in normal adult bone marrow, and that the CML repopulated cells have, in addition to their ability to sustain the clone, a greater innate resistance to the toxic effects that imatinib mesylate has in vivo on the majority population of more differentiated CML cells.